A bicistronic retroviral vector for protecting hematopoietic cells against antifolates and P-glycoprotein effluxed drugs.
Chemoresistance gene transfer is an experimental method to protect hematopoietic cells from the toxicity of anticancer drugs. Because multiple drugs are usually given together in cancer therapy, this strategy will ultimately require vectors expressing multiple chemoresistance genes. For this reason, we designed a bicistronic retroviral vector (HaMID) containing a modified human multidrug resistance-1 cDNA and a mutant human dihydrofolate reductase cDNA bearing a leucine to tyrosine substitution at codon 22 (L22Y). To determine if this vector would confer dual drug resistance to hematopoietic cells, recombinant retrovirus was used to transduce the human CEM T lymphoblastic cell line as well as primary murine myeloid progenitors. Growth suppression assays, using polyclonal transduced CEM cells, demonstrated increased resistance to taxol (13-fold), trimetrexate (8.9-fold), vinblastine (5.6-fold), methotrexate (2.5-fold), and etoposide (1.5-fold) when used as single agents. HaMID-transduced cells also grew at a logarithmic rate in the simultaneous presence of 25 nM taxol and 100 nM trimetrexate while control cells were entirely growth inhibited by this drug combination. Similarly, HaMID-transduced murine myeloid progenitors acquired increased resistance to taxol (2.9-fold) and trimetrexate (140-fold), and were able to form colonies in the simultaneous presence of both drugs. Our results suggest that retroviral transfer of HaMID into primary hematopoietic cells should reduce the myelosuppression associated with the combined use of antifolates and P-glycoprotein-effluxed drugs.
Galipeau
J
J
Department of Hematology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
Benaim
E
E
Spencer
H T
HT
Blakley
R L
RL
Sorrentino
B P
BP
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000096:biosynthesis / Q000235:genetics*; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects*; D002478:Cells, Cultured; D003001:Cloning, Molecular; D018432:Drug Resistance, Multiple; D005047:Etoposide / Q000009:adverse effects; D005493:Folic Acid Antagonists / Q000009:adverse effects*; D015870:Gene Expression; D005822:Genetic Vectors; D006412:Hematopoietic Stem Cells / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D006801:Humans; D008727:Methotrexate / Q000009:adverse effects; D017239:Paclitaxel / Q000009:adverse effects; D011533:Proviruses; D012190:Retroviridae / Q000235:genetics*; D013762:Tetrahydrofolate Dehydrogenase / Q000235:genetics*; D014170:Transformation, Genetic; D016597:Trimetrexate / Q000009:adverse effects; D014407:Tumor Cells, Cultured; D014747:Vinblastine / Q000009:adverse effects
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000972:Antineoplastic Agents, Phytogenic; D005493:Folic Acid Antagonists; D014747:Vinblastine; D005047:Etoposide; D013762:Tetrahydrofolate Dehydrogenase; D017239:Paclitaxel; D016597:Trimetrexate; D008727:Methotrexate